In silico clinical trials

Edge Total Intelligence Reports Full Year and Q4 2022 Results

Retrieved on: 
Tuesday, May 2, 2023
Partnership, U.S. Department of Defense Strategy for Operating in Cyberspace, Gartner, National Security Innovation Network, Bank statement, NCIA, IDIQ, Digital twin, OTCQB, Conversation, FSE, Joint All-Domain Command and Control, MRR, Digital transformation, Privacy Office of the U.S. Department of Homeland Security, SEDAR, Artificial intelligence, Digital, United States Department of the Air Force, Research, CTRL, In silico clinical trials, Cryptocurrency, Video game, Medical device, Security (finance), Arms industry, Automation, AI

“2022 was a tough and uncertain year for the enterprise software sector as many buyers adjusted their consumption in response to global uncertainty,” said Jim Barrett, CEO of edgeTI.

Key Points: 
  • “2022 was a tough and uncertain year for the enterprise software sector as many buyers adjusted their consumption in response to global uncertainty,” said Jim Barrett, CEO of edgeTI.
  • Established a strategic partnership with Silico, an AI-powered Business Process Simulation solution based in London England.
  • The partnership will expand edgeCore™ use in the rapidly growing AI-driven business simulation market.
  • Recruited system integrators and technology partners to expand into the new and growing Artificial Intelligence (AI) market.

BELLUS Health Reports Year 2022 Financial Results and Business Highlights

Retrieved on: 
Tuesday, March 21, 2023
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Workforce, CALM, RCC, Clinical trial, Otorhinolaryngology, Pharmacokinetics, American Academy, Gastroenterology, G&A, Pulmonology, Research, William Frankland (allergist), Development, US, Patient, Investment, Physician, Administration, Annual general meeting, TSX, BLU, Poster, FDA, Society, P2X3, Pharmaceutical industry, Nursing, Cryptocurrency, In silico clinical trials

The CALM Phase 3 clinical program was initiated in the fourth quarter of 2022, with patient enrollment ongoing.

Key Points: 
  • The CALM Phase 3 clinical program was initiated in the fourth quarter of 2022, with patient enrollment ongoing.
  • BELLUS Health conducted validation work on the VitaloJAK cough monitoring system comparing compressed vs. non-compressed recordings in a cohort of 45 SOOTHE Phase 2b trial participants.
  • BELLUS Health submitted a validation protocol and statistical analysis plan to the FDA in the fourth quarter of 2022.
  • Topline results from CALM-1 are expected in the second half of 2024, and topline results from CALM-2 in 2025.

Global Non-Animal Alternative Testing Market Predicted to Hit $29,390.20 Million, Growing at 13.0% CAGR from 2021 to 2030 [290-Pages] | Proclaimed by Research Dive

Retrieved on: 
Friday, June 10, 2022
Center for Urban and Regional Analysis, Chemical industry, Knowledge, Animal, Assay, Environment, Household, Food industry, Growth, Organic, Diabetes, Health, COVID-19, Research, NEW, Prevalence, Industry, Cosmetics, Molecular imaging, Pharmaceutical industry, CAGR, Diagnosis, In silico clinical trials, Technology

NEW YORK, June 10, 2022 /PRNewswire/ -- Research Dive has added a new report to its offerings titled, "Non-animal alternative testing Testing Market by Technology (Cell Culture Technology, High Throughput Technology, Molecular Imaging, and Omic Technology), Method (Cellular Assay, Biochemical Assay, In Silico, and Ex-vivo), End-user (Pharmaceutical Industry, Cosmetics & Household Products, Diagnostics, Chemical Industry, and Food Industry), and Regional Analysis (North America, Europe, Asia-Pacific, and LAMEA): Global Opportunity Analysis and Industry Forecast, 2021-2030".

Key Points: 
  • The rising need for animal cruelty-free drug development testing methods is fueling the global non-animal alternative testing market growth.
  • The global non-animal alternative testing market is expected to garner $29,390.20 million by 2030, growing at a CAGR of 13.0% from 2021 to 2030.
  • Key Segment Findings of the Non-Animal Alternative Testing Market:
    The market is segmented based on technology, method, end-user, and region.
  • As a result, the demand for non-animal alternative testing has greatly surged; which is fueling the non-animal alternative testing market growth amidst the pandemic period.

Global Non-Animal Alternative Testing Market Predicted to Hit $29,390.20 Million, Growing at 13.0% CAGR from 2021 to 2030 [290-Pages] | Proclaimed by Research Dive

Retrieved on: 
Friday, June 10, 2022
Center for Urban and Regional Analysis, Chemical industry, Knowledge, Animal, Assay, Environment, Household, Food industry, Growth, Organic, Diabetes, Health, COVID-19, Research, NEW, Prevalence, Industry, Cosmetics, Molecular imaging, Pharmaceutical industry, CAGR, Diagnosis, In silico clinical trials, Technology

NEW YORK, June 10, 2022 /PRNewswire/ -- Research Dive has added a new report to its offerings titled, "Non-animal alternative testing Testing Market by Technology (Cell Culture Technology, High Throughput Technology, Molecular Imaging, and Omic Technology), Method (Cellular Assay, Biochemical Assay, In Silico, and Ex-vivo), End-user (Pharmaceutical Industry, Cosmetics & Household Products, Diagnostics, Chemical Industry, and Food Industry), and Regional Analysis (North America, Europe, Asia-Pacific, and LAMEA): Global Opportunity Analysis and Industry Forecast, 2021-2030".

Key Points: 
  • The rising need for animal cruelty-free drug development testing methods is fueling the global non-animal alternative testing market growth.
  • The global non-animal alternative testing market is expected to garner $29,390.20 million by 2030, growing at a CAGR of 13.0% from 2021 to 2030.
  • Key Segment Findings of the Non-Animal Alternative Testing Market:
    The market is segmented based on technology, method, end-user, and region.
  • As a result, the demand for non-animal alternative testing has greatly surged; which is fueling the non-animal alternative testing market growth amidst the pandemic period.

Novadiscovery appoints Grégoire Boutonnet as Chief Operating Officer

Retrieved on: 
Thursday, July 22, 2021
Articles, Health sciences, Clinical research, Health, Computational science, Medical technology, Contract research organizations, Drug discovery, In silico clinical trials, Blockchain, Clinical trial, ERT

Lyon, France 22 July 2021: Novadiscovery (NOVA), a leading health tech company using in silico clinical trials to predict drug efficacy and optimize clinical trial development, today announces the appointment of Grgoire Boutonnet as Chief Operating Officer, effective immediately.

Key Points: 
  • Lyon, France 22 July 2021: Novadiscovery (NOVA), a leading health tech company using in silico clinical trials to predict drug efficacy and optimize clinical trial development, today announces the appointment of Grgoire Boutonnet as Chief Operating Officer, effective immediately.
  • Grgoire then joinedtelecoms service provider Cirpack, following its acquisition of Andrexen, as Chief Marketing and Product Officer.
  • He most recently held the position of Chief Strategy Officer at Experty.io, a blockchain-based knowledge sharing platform.
  • Grgoire Boutonnet, Chief Operating Officer of NOVA, said: I am thrilled to be joining the NOVA team at this exciting period of growth as we launch the Jink platform towards wider adoption in the clinical trial development space.

Novadiscovery raises Series A2 financing from Sanofi to advance JINKO, its best-in-class clinical trial simulation platform

Retrieved on: 
Tuesday, February 16, 2021
Health sciences, Clinical research, Health, Life sciences, Drug discovery, Pharmaceutical industry, Computational science, Medical technology, Sanofi, In silico clinical trials, Simulation, Clinical trial

Novadiscovery raises Series A2 financing from Sanofi to advance JINKO, its best-in-class clinical trial simulation platform

Key Points: 
  • Novadiscovery raises Series A2 financing from Sanofi to advance JINKO, its best-in-class clinical trial simulation platform
    Lyon, France 16 February 2021: Novadiscovery (NOVA), a leading health tech company offering JINKO, a best-in-class clinical trial simulation platform to predict drug efficacy and optimize clinical trial development, today announces that it has raised 2.5 million in a Series A2 financing round from Sanofi.
  • The funds will be used to advance NOVAs in silico clinical trial simulation platform, JINKO; to facilitate the Companys expansion into the US; and develop a COVID-19 disease model in collaboration with Sanofi.
  • Disease modeling and clinical trial simulation is increasingly being used in pharmaceutical development to support decision making.
  • This strategic investment reflects the strength of NOVAs clinical trial simulation technology and the growing awareness of its potential to transform drug R&D by accelerating and de-risking clinical development.

Novadiscovery raises Series A2 financing from Sanofi to advance JINKO, its best-in-class clinical trial simulation platform

Retrieved on: 
Tuesday, February 16, 2021
Health sciences, Clinical research, Health, Life sciences, Drug discovery, Pharmaceutical industry, Computational science, Medical technology, Sanofi, In silico clinical trials, Simulation, Clinical trial

Novadiscovery raises Series A2 financing from Sanofi to advance JINKO, its best-in-class clinical trial simulation platform

Key Points: 
  • Novadiscovery raises Series A2 financing from Sanofi to advance JINKO, its best-in-class clinical trial simulation platform
    Lyon, France 16 February 2021: Novadiscovery (NOVA), a leading health tech company offering JINKO, a best-in-class clinical trial simulation platform to predict drug efficacy and optimize clinical trial development, today announces that it has raised 2.5 million in a Series A2 financing round from Sanofi.
  • The funds will be used to advance NOVAs in silico clinical trial simulation platform, JINKO; to facilitate the Companys expansion into the US; and develop a COVID-19 disease model in collaboration with Sanofi.
  • Disease modeling and clinical trial simulation is increasingly being used in pharmaceutical development to support decision making.
  • This strategic investment reflects the strength of NOVAs clinical trial simulation technology and the growing awareness of its potential to transform drug R&D by accelerating and de-risking clinical development.

Insights on the Global Clinical Trials Market Analysis 2019 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 18, 2020
Health, Clinical trials, Health, Clinical research, Pharmaceutical industry, Medical research, Design of experiments, Clinical pharmacology, Drug discovery, Clinical trial, In silico clinical trials, Patient recruitment

The "Global Clinical Trials Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Clinical Trials Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.
  • The Global Clinical Trials market is expected to reach $69.41 billion by 2026 growing at a CAGR of 7.8% during 2018 to 2026.
  • A clinical trial is a type of research that studies a test or treatment given to people.
  • Clinical trials study how safe and helpful tests and treatments are.